Phase 3, unicentric, randomized clinical trial, with allocation concealment and intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y Gastroplasty to decrease the prescription of antihypertensive drugs maintaining normal levels of blood pressure, decrease systemic arterial blood pressure and other risk factors for cardiovascular events compared to clinical treatments of patients with arterial hypertension.
Randomization: The randomization list is electronically generated through specific software. A block randomization is conducted with varying block sizes at the rate of 1:1. Confidentiality of the randomization list is ensured by the central automated randomization system, through the Internet, available 24 hours a day (ACT Clinic - Sistema de Estudos Clínicos do IEP HCor). Blinding Scheme: Because the study involves a surgical procedure, investigators and patients cannot be blind for treatment allocated to patients. Roux-en-Y Gastroplasty Patients allocated to surgical treatment will be admitted to the hospital to be subjected to a Roux-en-Y gastric bypass with a biliopancreatic loop of 100cm and a alimentary limb of 150cm. Antihypertensive Treatment: The treatment of hypertension will be standardized for all study patients. Prescribed drugs will include preferably a renin-angiotensin blocking system drug and a calcium channels blocker, except if these are contraindicated or the patient has achieved good blood pressure control using other drugs prior to study recruitment. Other drugs can be added at discretion of the attending investigator to achieve a target blood pressure of 130 x 80 mmHg. Patients are treated individually for the other associated comorbidities. Obesity treatment in the control group includes dietary advice, motivation for the practice of physical activities, and drug treatments for diabetes and dyslipidemias if applicable. Laboratory tests and other exams: All patients will be subjected to the following measurements throughout the study: * Outpatient Blood Pressure Monitoring (ABPM) * Blood pressure measurements taken in doctors' offices: * Central pressure and associated measurements (SphygmoCor®) * Polysomnography * Anthropometry * Nutritional survey * Laboratory tests * Echocardiogram * Electrocardiogram * Abdominal ultrasound * Upper gastrointestinal endoscopy with H.pylori testing
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
Instituto Dante Pazzanese de Cardiologia
São Paulo, São Paulo, Brazil
Instituto do Coração - Hospital das Clínicas de São Paulo
São Paulo, São Paulo, Brazil
Hospital do Coração - Research Institute
São Paulo, Brazil
Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg
Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (\<140x90 mmHg), in 12 months.
Time frame: 12 months
Efficacy of Roux-en-Y Gastroplasty to Decrease the Number of Antihypertensive Drugs.
Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (\<140x90 mmHg).
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline in Blood Pressure Levels
Change on systemic blood pressure assessed by ambulatory blood pressure monitoring (ABPM).
Time frame: 12, 24, 36, 48 and 60 months
Effect on Central Blood Pressure Augmentation Index and Pulse Wave Velocity
Change on central blood pressure augmentation index and pulse wave velocity as measured by SphygmoCor device
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Systolic Blood Pressure
Absolute change from baseline in systolic blood pressure
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Diastolic Blood Pressure
Absolute change from baseline in diastolic blood pressure
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Weight Loss
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Absolute change from baseline on weight loss
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on BMI
Absolute change from baseline on BMI
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Waist Circumference
Absolute change from baseline on waist circumference
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Fasting Plasm Glucose Level, HbA1c and Insulin Resistance
Change from baseline on fasting plasm glucose level, HbA1c and insulin resistance
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on LDL-cholesterol Level
Absolute change from baseline on LDL-cholesterol level
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on HDL-cholesterol Level
Absolute change from baseline on HDL-cholesterol level
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Triglycerides Levels
Absolute change from baseline on triglycerides levels
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Uric Acid Levels
Absolute change from baseline on uric acid levels
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline on Ultra-sensitive CRP Levels
Absolute change from baseline on ultra-sensitive CRP levels
Time frame: 12, 24, 36, 48 and 60 months
Absolute Change From Baseline of Cardiovascular Risk
Absolute change from baseline of cardiovascular risk calculated by Framingham Score
Time frame: 12, 24, 36, 48 and 60 months
Change on Heart Anatomy
Change on heart anatomy as evaluated by echocardiogram
Time frame: 12, 24, 36, 48 and 60 months
Change on Sleep Quality
Change on sleep quality as evaluated by polysomnography
Time frame: 12, 24, 36, 48 and 60 months
Adverse Events
Describe the main adverse events
Time frame: At any time during the study period